Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799903 · ClinicalTrials.gov registry record · Phase 3
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 15,828
- Enrollment target
NCT00799903: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00799903 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 15,828 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1953% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00799903, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 15,828 participants
- Enrollment target
Study Summary
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.
Primary Outcome
CV death=death due to a CV cause, which included but was not limited to deaths resulting from stroke, arrhythmia, sudden death (witnessed/unwitnessed), MI, heart failure, pulmonary embolism, peripheral arterial disease, or complications of a CV procedure. Deaths not clearly attributable to non-CV causes are considered to be CV deaths. Acute MI=evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the dev
Interventions
- DRUG Placebo
- DRUG Darapladib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,828 participants |
| Start Date | 2008-12-01 |
| Est. Completion | 2013-10-17 |
| Phase | Phase 3 |
What the finished NCT00799903 record still lists
NCT00799903 is an interventional study that assigns participants to a tested intervention. Its 15,828 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1953% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00799903 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00799903 about?
NCT00799903 is a clinical study titled "The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial". This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.
What is the current status of trial NCT00799903?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 15,828 participants. The study started on 2008-12-01. Estimated completion is 2013-10-17.
What interventions are being tested in trial NCT00799903?
The interventions under investigation include: Placebo (DRUG), Darapladib (DRUG).
Who is sponsoring clinical trial NCT00799903?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00799903's enrollment target sits among peer trials
15,828 13th of 2000 higher than 1,988 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05447806 · 15,732 participants · NA
Diabetes Clinical Decision Support
- NCT01737528 · 16,000 participants
STS/ACC Transcatheter Valve Therapy Registry (TVT Registry)
- NCT06380114 · 16,000 participants · NA
Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination
- NCT07000357 · 15,100 participants · Phase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI